- Asia Pacific
- South Africa
- Hong Kong
- New Zealand
- Czech Republic
- United Kingdom
Recent Pfizer Press Releases
Pfizer Announces Positive Top-Line Results from Two Phase 3 Trials of Tofacitinib in Adults with Moderate-to-Severe Chronic Plaque Psoriasis4/22/14 8:00 am EDT
OPT Pivotal #1 and OPT Pivotal #2 Studies, Together with Three Other Phase 3 Trials, to Form Basis for Planned Psoriasis Indication Submission to Regulatory AuthoritiesNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis. The OPT Pivotal #1 and OPT Pivotal #2more...
4/18/14 1:20 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Eastern Daylight Time) on Thursday, April 24. To access the webcast, visit our website at www.pfizer.com/annualmeeting and click on the “Annual Meeting of Shareholders Webcast” link. Information on accessing and pre-registering for the live audio webcast will be available at www.pfizer.com beginningmore...
Pfizer’s Novel CDK 4/6 Inhibitor Palbociclib plus Letrozole Significantly Prolonged Progression-Free Survival in Patients with Advanced Breast Cancer4/6/14 10:30 am EDT
Final Phase 2 PALOMA-1 Data to Be Presented Today for Potential First-in-Class Palbociclib
Webcast of Conference Call with Securities Analysts to Review Data Scheduled for Today at 1:30 PDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced detailed results from the PALOMA-1 study, a randomized Phase 2 study of palbociclib (PD-0332991) in combination with letrozole. PALOMA-1 achieved its primary endpoint by significantly prolonging progression-free survival (PFS) compared with letrozole alone in post-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breastmore...
3/28/14 6:26 pm EDTNEW YORK--(BUSINESS WIRE)--Today the U.S. Food and Drug Administration (FDA) approved over-the-counter Nexium® 24HR (esomeprazole 20mg) marking a key step towards providing those who suffer from frequent heartburn broader access to a brand doctors and patients have trusted for years. In 2012, Pfizer acquired exclusive global rights from AstraZeneca to market non-prescription Nexium®. The addition of Nexium® 24HR to the Pfizer Consumer Healthcare portfolio expandsmore...
In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control 13/27/14 8:14 am EDT
Blood Pressure Control Key Factor in Stroke RiskPRINCETON, N.J., & NEW YORK--(BUSINESS WIRE)--Today the U.S. Food and Drug Administration (FDA) approved over-the-counter Nexium® 24HR (esomeprazole 20mg) marking a key step towards providing those who suffer from frequent heartburn broader access to a brand doctors and patients have trusted for years. In 2012, Pfizer acquired exclusive global rights from AstraZeneca to market non-prescription Nexium®. The addition of Nexium® 24HR to the Pfizer Consumer Healthcare portfolio expandsmore...
Bococizumab (RN316) Significantly Reduced LDL Cholesterol In Statin-Treated Adults With High Cholesterol In A Phase 2b Study13/27/14 8:00 am EDT
Results Presented at the American College of Cardiology’s (ACC) 63rd Annual Scientific Session in Washington D.C.
Phase 3 Program Focused on CV Outcomes in Patient Populations at High Risk for Cardiovascular EventsNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the Phase 2b results of a 24 week, randomized, placebo-controlled, dose-ranging study of investigational bococizumab, the proposed generic name for RN316. Statin treated patients with high cholesterol were randomized to various doses of either bococizumab twice or once monthly subcutaneous administration or placebo. The study met its primary endpoint across all doses, showing that bococizumab significantlymore...
Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPIN® In Very Young Children Born Small For Gestational Age3/26/14 8:00 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today the top-line results from a Phase 3B study evaluating the 24-month efficacy of GENOTROPIN® (somatropin) on the height in small-for-gestational-age (SGA) children 24-30 months old. The primary endpoint of the study was achieved: there was a statistically significant difference at 24 months in change from baseline height between patients treated with GENOTROPIN and those in the untreated control group, asmore...
3/25/14 5:10 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Monday, May 5, 2014. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2014 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.commore...
Pfizer Reports Positive Phase 3 Study Outcome Of XALKORI® (crizotinib) Compared To Chemotherapy In Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)3/25/14 8:30 am EDT
Crizotinib is the Only Agent That Demonstrated Superior PFS Over Chemotherapy in Two Global Randomized Studies in First- and Second-Line ALK-Positive Advanced NSCLCNEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that PROFILE 1014, a Phase 3 study of anaplastic lymphoma kinase (ALK) inhibitor XALKORI® (crizotinib), met its primary objective of significantly prolonging progression-free survival (PFS) in previously untreated patients with ALK-positive advanced non-squamous non-small cell lung cancer (NSCLC) when compared to standard platinum-based chemotherapy regimens. PROFILE 1014 is the second positive global Phase 3 studymore...
Pfizer Announces Detailed Results of OPT Compare Phase 3 Study of Tofacitinib 5 mg and 10 mg Twice Daily Compared to High-Dose ENBREL® in Adults with Moderate-to-Severe Chronic Plaque Psoriasis3/22/14 11:45 am EDT
Data from First of Five Phase 3 Studies in Psoriasis to be Presented Today During Oral Session at the 72nd Annual American Academy of Dermatology Meeting in Denver, CONEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today detailed results from OPT Compare (A3921080), a Phase 3 study of tofacitinib, the first in a new class of treatment, oral Janus kinase (JAK) inhibitors, the safety and efficacy of which are being investigated for the treatment of adults with moderate-to-severe chronic plaque psoriasis. Top-line results from OPT Compare were previously announced in October 2013. This is the first of five studies from themore...